LifeSiteNews has been permanently banned on YouTube. Click HERE to sign up to receive emails when we add to our video library.
June 24, 2021 (Children’s Health Defense) – The Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) said Wednesday there is a “likely association” of “mild” heart inflammation in adolescents and young adults after vaccination with an mRNA COVID vaccine and a warning statement is warranted.
According to a report by the COVID-19 Vaccine Safety Technical (VaST) Work Group, the risk of myocarditis or pericarditis following vaccination with the mRNA-based shots in adolescents and young adults is notably higher after the second dose and in males.
There have been more than 1,200 cases of myocarditis or pericarditis in 16- to-24-year-olds who received an mRNA COVID vaccine, according to a series of slide presentations published Wednesday at the ACIP meeting.
Myocarditis is inflammation of the heart muscle that can lead to cardiac arrhythmia and death. According to researchers at the National Organization for Rare Disorders, myocarditis can result from infections, but “more commonly the myocarditis is a result of the body’s immune reaction to the initial heart damage.”
Pericarditis is often used interchangeably with myocarditis and refers to inflammation of the pericardium, the thin sac surrounding the heart.
According to the CDC, men under 30 make up the bulk of the cases and most cases appeared to be mild. Of the 295 people who developed the condition and have been discharged, 79% have fully recovered, according to the presentation. Nine people were hospitalized, with two in intensive care as of June 11, according to the CDC.
The agency said through June 11 there have been 267 cases of myocarditis or pericarditis reported after receiving one dose of the mRNA vaccines and 827 reported cases after two doses. There are 132 additional cases where the number of doses received is unknown.
Dr. Tom Shimabukuro, deputy director of the CDC’s Immunization Safety Office, said in a presentation that data from one of the agency’s safety monitoring systems — Vaccine Safety Datalink (VSD) — suggests a rate of 12.6 cases per million in the three weeks after the second shot in 12- to 39-year-olds.
Dr. Meryl Nass, an internal medicine physician, pointed out several flaws in the data used during the ACIP’s presentation:
“As of now, two major ways the rate of myocarditis were minimized [during the presentation] was to lump people from age 39 and down –– even though the highest rates [of myocarditis] are in the youngest kids. This waters down the rate. The other method was to only include a very narrow window of time after vaccinations started in the 12-15 age group, thus omitting the vast majority of second doses, which is when about 75% or more of the myocarditis cases occur. Also, the genders were sometimes mixed. And rates in girls are much lower than boys.”
During the presentation, Dr. Megan Wallance stated the overall efficacy of Pfizer’s COVID vaccine in the 12 to 15 age group is 100% and Moderna’s was comparable. Wallace then did a risk/benefit analysis comparing myocarditis cases versus hospitalization rates for COVID in people between the ages of 12 and 29.
“The problem with her analysis is that now the myocarditis rate used is too low. But the risk from COVID is magnified,” Nass said.
Nass further questioned why the ACIP did not include any of the almost 6,000 deaths reported to the Vaccine Adverse Events Reporting System (VAERS) in the risk pool when determining risk and benefits.
During the presentation, a CDC spokesperson said vaccine considerations for people with a history of myocarditis and pericarditis will be updated:
- People with a history of pericarditis will be encouraged to receive any FDA-authorized COVID vaccine.
- Anyone with a history of myocarditis will be encouraged to receive an FDA-authorized COVID vaccine if their heart has recovered.
- People with a history of myocarditis after the first dose of an mRNA vaccine will be encouraged to defer the second dose until more information is known, but if the heart has healed, a second dose could be considered.
CDC officials said they are gathering more data to fully understand the potential risks, how to manage them and whether there are any long-term issues.
Officials emphasized the benefits of vaccines outweigh the risks, and noted that for every million doses of mRNA vaccine given, there are far more COVID cases and hospitalizations prevented compared to the number of potential myocarditis cases.
Public commenters chastise CDC for overstating risks of COVID for children
Public commenters — during the public comment session — chastised the CDC and its advisory committee for adopting the stance that benefits of experimental COVID vaccines outweigh the risks in teens, when teens have a relative zero risk of dying from COVID, and are at a very low risk of experiencing adverse events.
According to the CDC, COVID adolescent hospitalization rates in the 12-17 age group was 2.1 per 100,000 in early January 2021, and 1.3 per 100,000 in April. Of 204 hospitalizations assessed by the CDC from March 1, 2020 to April 24, 2021, no deaths occurred.
Two papers published May 19 in the journal of Hospital Pediatrics found pediatric hospitalizations for COVID were overcounted by at least 40%, carrying potential implications for nationwide figures used to justify vaccinating children.
Another study, referenced by a public commenter, showed in many cases COVID diagnosis was incidental to the underlying reason the patient was hospitalized — meaning there was no documentation of COVID symptoms prior to hospitalization.
The first public commenter said [time stamp: 3:38]:
“As of June 11, looking at myocarditis and pericarditis alone, there have been 197 reports in 30-39 year olds, 392 reports in 19-29 year olds and 279 reports in 18 years and younger. Looking at the Harvard Pilgrim study which states that less than 1% of adverse events were reported to VAERS, it is reasonable to assume that these numbers are much higher than are being reported. From the meeting here today, we heard that there have been more than 1,200 cases of myocarditis and pericarditis, mostly in people under 30. The numbers are growing quickly. This should ring the alarm for all of you. It certainly does for me.”
William Houston, associated with a public research organization focused on public health and safety, said during public comment the CDC is withholding VAERS data and delaying publishing adverse event reports. Actual numbers, Houston estimated, are 3 to 14 times higher than what’s been made public to date.
This is consistent with several stories of myocarditis in teens recently covered by The Defender — all of whom reported to VAERS and were given I.D. numbers, but are not yet published in the VAERS database.
Another public commenter [time stamp 3:56:28], a parent and parent advocate, expressed concern that ACIP members were instructed to vote during a previous meeting, even though data were not yet available. She also questioned why the different reporting systems are using different age group ranges.
She chastised the committee’s canceling of the emergency meeting on heart inflammation scheduled for June 8 and noted that in December, the ACIP met multiple times during weekends when the manufacturers wanted their vaccine approvals.
Public commentator [time stamp 3:59:30] Dr. Leslie Moore, physician and mother, said the data on COVID vaccines are atrocious and frightening. Moore said vaccines are still investigational and there is no comprehensive monitoring and data collection.
“People get shot up and left to deal with the consequences on their own,” Moore said.
“All we have is the VAERS system, which is voluntary self-reporting. We know VAERS only captures 1-10% of all adverse events. Adverse events are grossly under-reported for a variety of reasons. I looked at open VAERS this morning. These products have amassed 6,000 deaths and 20,000 hospitalizations in the U.S, alone –– which is more than the other 70 vaccines for the last 30 years combined. That is with gross under-reporting and a two-month backlog. Let’s face it, these vaccines are not safe.
“Now let’s consider these products for children. What is the risk-benefit analysis? Children are at a statistically insignificant risk from COVID-19, so there is no benefit to vaccination, and you can’t vaccinate them to benefit others. These shots don’t work that way. They don’t prevent infection or transmission. Your shot, at best, protects you from severe symptoms, no one else.
“Children have no benefit, only risks from these products. Any child injured or killed by the shot likely would have done fine with the virus and received broad and lasting natural immunity.”